These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 27283290)

  • 1. Prognostic markers and response to vandetanib therapy in sporadic medullary thyroid cancer patients.
    Tiedje V; Ting S; Walter RF; Herold T; Worm K; Badziong J; Zwanziger D; Schmid KW; Führer D
    Eur J Endocrinol; 2016 Sep; 175(3):173-80. PubMed ID: 27283290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.
    Wells SA; Gosnell JE; Gagel RF; Moley J; Pfister D; Sosa JA; Skinner M; Krebs A; Vasselli J; Schlumberger M
    J Clin Oncol; 2010 Feb; 28(5):767-72. PubMed ID: 20065189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vandetanib and the management of advanced medullary thyroid cancer.
    Campbell MJ; Seib CD; Gosnell J
    Curr Opin Oncol; 2013 Jan; 25(1):39-43. PubMed ID: 23202050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Vandetanib, in the management of patients with locally advanced or metastatic medullary thyroid carcinomas].
    Chougnet CN; Schlumberger M; Leboulleux S; Baudin E
    Bull Cancer; 2014 Sep; 101(9):891-5. PubMed ID: 25296193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetics of medullary thyroid cancer: An overview.
    Accardo G; Conzo G; Esposito D; Gambardella C; Mazzella M; Castaldo F; Di Donna C; Polistena A; Avenia N; Colantuoni V; Giugliano D; Pasquali D
    Int J Surg; 2017 May; 41 Suppl 1():S2-S6. PubMed ID: 28506408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib.
    Kraft IL; Akshintala S; Zhu Y; Lei H; Derse-Anthony C; Dombi E; Steinberg SM; Lodish M; Waguespack SG; Kapustina O; Fox E; Balis FM; Merino MJ; Meltzer PS; Glod JW; Shern JF; Widemann BC
    Clin Cancer Res; 2018 Feb; 24(4):753-765. PubMed ID: 29187393
    [No Abstract]   [Full Text] [Related]  

  • 7. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer.
    Robinson BG; Paz-Ares L; Krebs A; Vasselli J; Haddad R
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2664-71. PubMed ID: 20371662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma.
    Fox E; Widemann BC; Chuk MK; Marcus L; Aikin A; Whitcomb PO; Merino MJ; Lodish M; Dombi E; Steinberg SM; Wells SA; Balis FM
    Clin Cancer Res; 2013 Aug; 19(15):4239-48. PubMed ID: 23766359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating miR-375 as a novel prognostic marker for metastatic medullary thyroid cancer patients.
    Romeo P; Colombo C; Granata R; Calareso G; Gualeni AV; Dugo M; De Cecco L; Rizzetti MG; Zanframundo A; Aiello A; Carcangiu ML; Gloghini A; Ferrero S; Licitra L; Greco A; Fugazzola L; Locati LD; Borrello MG
    Endocr Relat Cancer; 2018 Mar; 25(3):217-231. PubMed ID: 29298817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer.
    Lam ET; Ringel MD; Kloos RT; Prior TW; Knopp MV; Liang J; Sammet S; Hall NC; Wakely PE; Vasko VV; Saji M; Snyder PJ; Wei L; Arbogast D; Collamore M; Wright JJ; Moley JF; Villalona-Calero MA; Shah MH
    J Clin Oncol; 2010 May; 28(14):2323-30. PubMed ID: 20368568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vandetanib in a Child Affected by Neurofibromatosis Type 1 and Medullary Thyroid Carcinoma with Both
    Demir Gündoğan B; Sağcan F; Tuğ Bozdoğan S; Balcı Y; Tuncel Daloğlu F; Çağlar Çıtak E
    J Clin Res Pediatr Endocrinol; 2021 Aug; 13(3):342-346. PubMed ID: 32702947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic treatment and management approaches for medullary thyroid cancer.
    Ernani V; Kumar M; Chen AY; Owonikoko TK
    Cancer Treat Rev; 2016 Nov; 50():89-98. PubMed ID: 27664392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Control of Hypercortisolism by Vandetanib in a Case of Medullary Thyroid Carcinoma with a Somatic RET Mutation.
    Paepegaey AC; Cochand-Priollet B; Louiset E; Sarfati PO; Alifano M; Burnichon N; Bienvenu-Perrard M; Lahlou N; Bricaire L; Groussin L
    Thyroid; 2017 Apr; 27(4):587-590. PubMed ID: 28068878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer.
    Koehler VF; Adam P; Frank-Raue K; Raue F; Berg E; Hoster E; Allelein S; Schott M; Kroiss M; Spitzweg C
    Thyroid; 2021 Mar; 31(3):459-469. PubMed ID: 32781914
    [No Abstract]   [Full Text] [Related]  

  • 15. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.
    Elisei R; Cosci B; Romei C; Bottici V; Renzini G; Molinaro E; Agate L; Vivaldi A; Faviana P; Basolo F; Miccoli P; Berti P; Pacini F; Pinchera A
    J Clin Endocrinol Metab; 2008 Mar; 93(3):682-7. PubMed ID: 18073307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland.
    Ciampi R; Romei C; Pieruzzi L; Tacito A; Molinaro E; Agate L; Bottici V; Casella F; Ugolini C; Materazzi G; Basolo F; Elisei R
    J Endocrinol Invest; 2017 Jan; 40(1):55-62. PubMed ID: 27535135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcriptional targeting of oncogene addiction in medullary thyroid cancer.
    Valenciaga A; Saji M; Yu L; Zhang X; Bumrah C; Yilmaz AS; Knippler CM; Miles W; Giordano TJ; Cote GJ; Ringel MD
    JCI Insight; 2018 Aug; 3(16):. PubMed ID: 30135308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vandetanib therapy in medullary thyroid cancer.
    Grabowski P; Briest F; Baum RP; Zaknun JJ; Kulkarni HR; Zeitz M; Hörsch D
    Drugs Today (Barc); 2012 Nov; 48(11):723-33. PubMed ID: 23170308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular genetics, therapeutics and RET inhibitor resistance for medullary thyroid carcinoma and future perspectives.
    Zhang Y; Zheng WH; Zhou SH; Gu JL; Yu Q; Zhu YZ; Yan YJ; Zhu Z; Shang JB
    Cell Commun Signal; 2024 Sep; 22(1):460. PubMed ID: 39342195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I/II Trial of Vandetanib and Bortezomib in Adults with Locally Advanced or Metastatic Medullary Thyroid Cancer.
    Del Rivero J; Edgerly M; Ward J; Madan RA; Balasubramaniam S; Fojo T; Gramza AW
    Oncologist; 2019 Jan; 24(1):16-e14. PubMed ID: 30297385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.